Ueki T, Nakata K, Mawatari F, Tsuruta S, Ido A, Ishikawa H, Nakao K, Kato Y, Ishii N, Eguchi K
The First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852, Japan.
Int J Mol Med. 1998 Apr;1(4):671-5. doi: 10.3892/ijmm.1.4.671.
Gene therapy using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of the 0.3-kb human alpha-fetoprotein (AFP) gene promoter (LNAF0.3TK virus) in combination with ganciclovir (GCV) treatment was performed in athymic mice harboring AFP-producing HuH-7 human hepatoma cells. GCV treatment resulted in pronounced growth inhibition of the virus-infected HuH-7 xenograft in mice, but did not affect growth of the parental xenograft. These results indicate that the AFP gene promoter sequence allows enough therapeutic gene expression to induce the GCV-mediated cytotoxicity in vivo in AFP-producing human hepatoma cells.
在携带产生甲胎蛋白的HuH-7人肝癌细胞的无胸腺小鼠中，进行了基因治疗，该治疗使用一种逆转录病毒载体，该载体携带在0.3 kb人甲胎蛋白（AFP）基因启动子控制下的单纯疱疹病毒胸苷激酶基因（LNAF0.3TK病毒），并联合更昔洛韦（GCV）治疗。GCV治疗导致小鼠中病毒感染的HuH-7异种移植瘤明显生长抑制，但不影响亲代异种移植瘤的生长。这些结果表明，AFP基因启动子序列允许足够的治疗性基因表达，以在产生AFP的人肝癌细胞中在体内诱导GCV介导的细胞毒性。
